1. Home
  2. DCBO vs BBNX Comparison

DCBO vs BBNX Comparison

Compare DCBO & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Docebo Inc.

DCBO

Docebo Inc.

HOLD

Current Price

$16.26

Market Cap

632.5M

Sector

N/A

ML Signal

HOLD

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$13.68

Market Cap

613.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCBO
BBNX
Founded
2016
2015
Country
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
632.5M
613.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DCBO
BBNX
Price
$16.26
$13.68
Analyst Decision
Buy
Strong Buy
Analyst Count
9
12
Target Price
$33.78
$27.08
AVG Volume (30 Days)
242.5K
997.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.67
$35.03
Revenue Next Year
$7.43
$33.24
P/E Ratio
$24.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.05
$8.89
52 Week High
$42.53
$32.71

Technical Indicators

Market Signals
Indicator
DCBO
BBNX
Relative Strength Index (RSI) 24.75 32.52
Support Level $18.50 $13.25
Resistance Level $19.15 $15.53
Average True Range (ATR) 0.82 1.16
MACD -0.09 0.47
Stochastic Oscillator 4.95 54.88

Price Performance

Historical Comparison
DCBO
BBNX

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

Share on Social Networks: